109. 非典型溶血性尿毒症症候群 Atypical hemolytic uremic syndrome Clinical trials / Disease details
臨床試験数 : 114 / 薬物数 : 36 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11
Showing 1 to 5 of 5 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-004129-18-LT (EUCTR) | 15/03/2019 | 29/01/2019 | An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from their initial study An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from the ... | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ... | Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: COVERSIN | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom;India | ||
| 2 | EUCTR2016-004129-18-NL (EUCTR) | 14/02/2018 | 16/11/2017 | An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initial study An extension study on Coversinfor Patients with PNH and aHUS who received benefit from their initial ... | CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ... | Product Name: Coversin Product Code: rVA576 INN or Proposed INN: COVERSIN Other descriptive name: COVERSIN Product Name: Coversin Product Code: rVA576 INN or Proposed INN: COVERSIN Other descriptive name: COVER ... | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | Argentina;Poland;Lithuania;Netherlands;United Kingdom | ||
| 3 | EUCTR2017-000064-15-GB (EUCTR) | 14/09/2017 | 28/06/2017 | A study of Safety and Efficacy of Coversin in adult aHUS subjects | A Phase 2, single arm study of Safety and Efficacy of Coversin in adult aHUS subjects | Atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 20.0;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 20.0;Level: PT;Classification code 10018 ... | Product Name: Coversin Product Code: rVA576 INN or Proposed INN: Coversin Other descriptive name: COVERSIN Product Name: Coversin Product Code: rVA576 INN or Proposed INN: Coversin Other descriptive name: COVER ... | Akari Therapeutics Plc | ,NULL | Not Recruiting | Female: yes Male: yes | 10 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ... | United Kingdom | ||
| 4 | EUCTR2016-004129-18-GB (EUCTR) | 17/03/2017 | 21/12/2016 | An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from their initial study An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from the ... | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ... | Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: rVA576 | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom | ||
| 5 | EUCTR2016-004129-18-PL (EUCTR) | 07/03/2017 | 18/01/2017 | An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initial study An extension study on Coversinfor Patients with PNH and aHUS who received benefit from their initial ... | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ... | Product Name: rVA576 (Coversin) Product Code: rVA576 INN or Proposed INN: rVA576 (COVERSIN) Other descriptive name: rVA576 (COVERSIN) Product Name: rVA576(Coversin) Product Code: rVA576 INN or Proposed INN: rVA576(COVERSIN) Other descrip ... | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom |